The closing price of Pieris Pharmaceuticals Inc (NASDAQ: PIRS) was $0.17 for the day, up 5.92% from the previous closing price of $0.16. In other words, the price has increased by $+0.0095 from its previous closing price. On the day, 696497 shares were traded.
Ratios:
Our analysis of PIRS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.05 and its Current Ratio is at 2.05. In the meantime, Its Debt-to-Equity ratio is 0.40 whereas as Long-Term Debt/Eq ratio is at 0.00.
On May 14, 2019, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $5.Robert W. Baird initiated its Outperform rating on May 14, 2019, with a $5 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 25 when KIRITSY CHRISTOPHER P bought 10,000 shares for $0.85 per share. The transaction valued at 8,500 led to the insider holds 20,000 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PIRS now has a Market Capitalization of 16.81M and an Enterprise Value of -15.70M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.36 while its Price-to-Book (P/B) ratio in mrq is 0.55. Its current Enterprise Value per Revenue stands at -0.33 whereas that against EBITDA is 1.28.
Stock Price History:
Over the past 52 weeks, PIRS has reached a high of $1.53, while it has fallen to a 52-week low of $0.14. The 50-Day Moving Average of the stock is 0.1688, while the 200-Day Moving Average is calculated to be 0.3152.
Shares Statistics:
PIRS traded an average of 491.65K shares per day over the past three months and 322.73k shares per day over the past ten days. A total of 98.85M shares are outstanding, with a floating share count of 91.49M. Insiders hold about 7.45% of the company’s shares, while institutions hold 39.41% stake in the company. Shares short for PIRS as of Feb 15, 2024 were 66.22k with a Short Ratio of 0.13, compared to 163.58k on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.07% and a Short% of Float of 0.07%.
Earnings Estimates
The firm’s stock currently is rated by 0 analysts. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was -$0.11. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 1 analysts. It ranges from a high estimate of $2.24M to a low estimate of $2.24M. As of the current estimate, Pieris Pharmaceuticals Inc’s year-ago sales were $5.85M, an estimated decrease of -61.70% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $2.24M, a decrease of -65.50% less than the figure of -$61.70% in the same quarter last year. There is a high estimate of $2.24M for the next quarter, whereas the lowest estimate is $2.24M.
A total of 1 analysts have provided revenue estimates for PIRS’s current fiscal year. The highest revenue estimate was $31.98M, while the lowest revenue estimate was $31.98M, resulting in an average revenue estimate of $31.98M. In the same quarter a year ago, actual revenue was $25.9M, up 23.50% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $6.62M in the next fiscal year. The high estimate is $6.62M and the low estimate is $6.62M. The average revenue growth estimate for next year is down -79.30% from the average revenue estimate for this year.
